



Attorney Docket No.: 6607.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Petersen et al.

Application No.: 10/700,778

Group Art Unit: 1645

Filed: November 4, 2003

Examiner: To be assigned

For: PHARMACEUTICAL COMPOSITION COMPRISING A TISSUE FACTOR
ANTAGONIST AND PROTEIN C POLYPEPTIDES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 01/59084
2. WO 92/15686
3. WO 94/27631
4. WO 96/12800


5. WO 97/47651
6. WO 90/03390
7. WO 95/00541
8. WO 96/18653
9. WO 01/21661
10. WO 99/51743
11. WO 96/40921
12. EP 500800
13. US 6001978
14. US 5223427
15. Chan, J CY et al., J Clin Invest, Vol. 105 (7), pp. 897-903 (April 2000)
16. Holst, J et al., Eur J Vasc Endovasc Surg, Vol. 15 (6), pp. 515-20 (June 1998)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: September 16, 2004

Respectfully submitted,


Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6607.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Petersen et al.

Serial No.: 10/700,778

Group Art Unit: 1645

Filed: November 4, 2003

Examiner: To be assigned

For: PHARMACEUTICAL COMPOSITION COMPRISING A TISSUE FACTOR
ANTAGONIST AND PROTEIN C POLYPEPTIDES

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **September 16, 2004**

Csaba Attila Szokolczai
(name of person mailing paper)

Csaba Attila Szokolczai
(signature of person mailing paper)

Serial No. 10/700,778

Applicant **Petersen et al.**

Group 1645

DIFFERENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		US 6001978					
		US 5223427					

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 01/59084						
		WO 92/15686						
		WO 94/27631						
		WO 96/12800						
		WO 97/47651						

[illegible]

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6607.200-US

Serial No. 10/700,778

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Petersen et al.**Filing Date **November 4, 2003**Group **1645**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 90/03390						
	WO 95/00541						
	WO 96/18653						
	WO 01/21661						
	WO 99/51743						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6607.200-US

Serial No. 10/700,778

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Petersen et al.**

(Use several sheets if necessary)

Filing Date **November 4, 2003**Group **1645**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 96/40921						
		EP 500800						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.